Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
Leading USA based genetic testing brand officially enters the Indian market
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The Product will be manufactured at the company's facility in Bengaluru
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Profit after tax (before exceptional items) up 23% to Rs 215 crores
This production block consists of chemical synthesis reactions and clean rooms areas to produce final API
Subscribe To Our Newsletter & Stay Updated